Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma

Listen to Frederick L. Locke, MD, answer audience questions from a live CCO Webinar focused on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with lymphomas.
Frederick L. Locke, MD
Released: March 18, 2021

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:

  • How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL?
  • Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?
  • How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?
  • How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?

Presenter:

Frederick L. Locke, MD
Co-Leader
Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director and Medical Director
Immune Cell Therapy Program
Moffitt Cancer Center
Tampa, Florida

Acknowledgements

Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Related Content

Commentary on considerations affecting therapy recommendations for patients with myeloma in the evolving treatment landscape, from Clinical Care Options (CCO)

Brian G.M. Durie, MD
Program Director
Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD
Released: December 7, 2021

Commentary from Dr. Julie Vose on how to select therapy for patients with EBV-positive PTLD, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 6, 2021

Downloadable PDF resource guide with key information and resources for optimal management of patients with T-cell lymphomas, from clinical care options (CCO)

Talha Khan, PharmD, BCOP Released: December 6, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue